Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vascular Risk Clear all
Active, not recruiting Phase 4 Interventional

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

NCT06249165
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 23, 2026, 8:57 PM EDT
Completed No phase listed Observational

The Framingham Study: Examining DNA Markers and Links to Diseases

NCT00062777
View directory record Official record
Conditions
Vascular Diseases
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 8:57 PM EDT
Completed Phase 2 Interventional

Interventions to Improve Hypertension Control and Reduce Cardiovascular Disease Risk

NCT00201136
View directory record Official record
Conditions
Hypertension
Interventions
Lifestyle interventions to lower blood pressure for patients, MD CQI-type intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
25 Years and older
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 23, 2026, 8:57 PM EDT
Completed Phase 3 Interventional Results available

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

NCT02525939
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
dalcetrapib, Placebo
Drug
Lead sponsor
DalCor Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
6,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
122
States / cities
Alexander City, Alabama • Huntsville, Alabama • Mobile, Alabama + 119 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Jul 23, 2026, 8:57 PM EDT
Completed Not applicable Interventional

Evaluating Weight Loss Programs for Obese People at Risk for Heart Disease (The POWER Study)

NCT00783315
View directory record Official record
Conditions
Obesity
Interventions
Call-Center Directed (CCD) Weight Loss Program, In-Person Directed (IPD) Weight Loss Program, Self-Directed Weight Loss Program
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 23, 2026, 8:57 PM EDT
Recruiting Not applicable Interventional

Preparing FIM-BCS - A Lifestyle Modification for African-American Breast Cancer Survivors

NCT06504914
View directory record Official record
Conditions
Hypertension, Obesity, Nutrition, Healthy
Interventions
Assigned Interventions
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 23, 2026, 8:57 PM EDT
Completed No phase listed Observational

Diagnostic Investigation of Sudden Cardiac Event Risk

NCT00500708
View directory record Official record
Conditions
Arrhythmia, Cardiovascular Diseases, Heart Failure, CVD
Interventions
Not listed
Lead sponsor
CardioDx
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Anchorage, Alaska • Palo Alto, California • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Jul 23, 2026, 8:57 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes

NCT07095426
View directory record Official record
Conditions
Metabolic Syndrome, Healthy Participants, Metabolically Healthy Obesity, Metabolically Abnormal Obesity
Interventions
inulin
Dietary Supplement
Lead sponsor
Ball State University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Muncie, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 23, 2026, 8:57 PM EDT
Completed Phase 2 Interventional

Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

NCT00240643
View directory record Official record
Conditions
Fibrillation, Atrial, Atrial Fibrillation
Interventions
SB424323
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Mobile, Alabama • Troy, Michigan • Akron, Ohio + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Jul 23, 2026, 8:57 PM EDT
Terminated Phase 3 Interventional

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

NCT03267108
View directory record Official record
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
INOpulse®, Placebo, Open Label Extension
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 23, 2026, 8:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lifetime Risk for Cardiovascular Disease Among Non-White Ethnic Groups

NCT00377702
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Disease, Heart Failure, Congestive, Atrial Fibrillation
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Jul 23, 2026, 8:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Standardizing Emergency Work-ups Around Risk Data

NCT03286179
View directory record Official record
Conditions
Acute Coronary Syndrome, Chest Pain, Risk Reduction
Interventions
modified HEART score and/or Emergency Department Assessment of Chest pain Risk Score (EDACS)
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
13,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
12
States / cities
Antioch, California • Fremont, California • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jul 23, 2026, 8:57 PM EDT
Terminated Phase 2 Interventional Results available

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

NCT01534143
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
pharmacological study, tacrolimus, sirolimus, anti-thymocyte globulin, fludarabine phosphate, busulfan, bortezomib, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis
Other · Drug · Biological + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jul 23, 2026, 8:57 PM EDT
Completed Phase 1 Interventional

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

NCT02697383
View directory record Official record
Conditions
Multiple Myeloma, High Risk Smoldering Multiple Myeloma
Interventions
Ixazomib (MLN9708), Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated May 12, 2024 · Synced Jul 23, 2026, 8:57 PM EDT
Completed No phase listed Observational

Linking Former Inmates to Primary Care

NCT01863290
View directory record Official record
Conditions
Hypertension, Substance Abuse, Asthma, Depression
Interventions
Primary care redesign
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
816 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Martinez, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Jul 23, 2026, 8:57 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Jul 23, 2026, 8:57 PM EDT
Completed No phase listed Observational Results available

Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)

NCT00590980
View directory record Official record
Conditions
Vertebrobasilar Insufficiency, Ischemic Attack, Transient, Cerebrovascular Disorder, Brain Ischemia, Stroke
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 23, 2026, 8:57 PM EDT
Completed Not applicable Interventional Results available

Myocardial Infarction, COmbined-device, Recovery Enhancement Study

NCT03760796
View directory record Official record
Conditions
Acute Myocardial Infarction, Coronary Artery Disease, Acute Coronary Syndrome, Myocardial Infarction
Interventions
Corrie Health Digital Platform
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Jul 23, 2026, 8:57 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

NCT03315754
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
TOOKAD Soluble 4 mg/kg
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Jul 23, 2026, 8:57 PM EDT
Terminated Phase 4 Interventional Results available

Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging

NCT02114697
View directory record Official record
Conditions
Atherosclerosis
Interventions
Statin therapy, Lifestyle modification
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
22 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jul 23, 2026, 8:57 PM EDT
Completed Not applicable Interventional Results available

EVEREST II Pivotal Study High Risk Registry (HRR)

NCT01940120
View directory record Official record
Conditions
Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation, Mitral Insufficiency
Interventions
Percutaneous mitral valve repair using MitraClip implant
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Evanston, Illinois • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Jul 23, 2026, 8:57 PM EDT
Terminated Phase 2 Interventional Results available

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT02128230
View directory record Official record
Conditions
Multiple Myeloma
Interventions
myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D
Device · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jul 23, 2026, 8:57 PM EDT
Withdrawn Phase 2 Interventional

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

NCT00004039
View directory record Official record
Conditions
Lymphoma
Interventions
recombinant interferon alfa, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Jul 23, 2026, 8:57 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

NCT06550895
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Talquetamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Iowa City, Iowa • Louisville, Kentucky • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 8:57 PM EDT